- Entry
- $2.83
- Final
- $3.19 +12.7%
- Target
- —
- Score
- +1.00
CABA Big news. CABA abstracts for the upcoming EULAR conference are now published and online. Screenshots of all the abstracts here. This morning, I found CABA’s abstracts it will present in 2 weeks at the EULAR conference in London published on EULAR’s website in a 2500 page compendium of abstracts for the conference. Link below. The two big most important ones concern the Phase 1/2 results of safety and efficacy of RESE-CEL in severe refractory SLE and lupus nephritis and …
— ORIGINAL POST ·
Breaking News - CABA’s Phase 1/2 RESET Clinical Trial Safety and Efficacy Results Abstracts to Be Presented at EULAR Conference in London Published HERE TWO Weeks Early - Lupus, Scleroderma and Myositis - RESE-CEL Effective against SLE, Lupus Nephritis and One Form of Myositis
· r/pennystocks
· May 22, 2026